Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
NCT05833217
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Long COVID
- Insulin Resistance
- Insulin Sensitivity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Stanford University
- Last updated on ClinicalTrials.gov
- December 4, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Stanford Health · Palo Alto, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.